Market Overview:
The global vaccine particulate adjuvants market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases and cancer, and the rising demand for vaccines globally. Based on type, the global vaccine particulate adjuvants market can be segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The oral segment is expected to account for the largest share of the global vaccine particulate adjuvants market in 2018. This segment is projected to grow at a CAGR of 11% during the forecast period from 2018 to 2030. This growth can be attributed to factors such as ease-of-use and lower cost as compared with other types of vaccine adjuvants available in the market. Based on application,the global vaccine particulate adjuvantsmarket can be divided into infectious diseasesand cancer.
Product Definition:
A vaccine adjuvant is a substance that is added to a vaccine to improve the effectiveness of the vaccine. The most common adjuvants are aluminum salts, which are added to many vaccines in order to increase the immune response. Vaccine particulate adjuvants are also used in some vaccines. These adjuvants consist of small particles that help promote an immune response.
Oral:
Oral adjuvants are used in vaccines to enhance their ability to stimulate an immune response. They can be administered together with other vaccine components such as alum, virosomes, and cytokines.
Subcutaneous:
Subcutaneous (SC) is a type of vaccine particulate adjuvant that aids in the immune response to fight against diseases such as cholera, influenza, and smallpox. It works by stimulating the body’s immune system to produce antibodies and other protective proteins. The most commonly used form of subcutaneous vaccine adjuvant is alum salts because they are inexpensive, easily available, well characterized chemically and have been used in numerous successful immunization programs globally.
Application Insights:
On the basis of application, the global vaccine particulate adjuvants market is segmented into infectious diseases, cancer and others. The infectious diseases segment dominated the overall industry in terms of revenue share in 2017. This can be attributed to factors such as growing immunization rates against a number of common infectious diseases and high disease burden due to these infections. In addition, there is an increasing focus on new product development for various vaccines including flu vaccines by major companies which are aimed at improving patient compliance and enhancing effectiveness.
The other applications include cardiovascular disease (CVD), diabetes mellitus type 2, osteoporosis treatment drugs etc. These segments are expected to witness significant growth over the forecast period owing to rising usage rates for various products across different regions coupled with increasing awareness about preventive healthcare measures among individuals concerned with these disorders or conditions.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of vaccine developers and manufacturers coupled with high R&D expenditure by government is some of the major factors contributing to its growth. In addition, increasing demand for vaccines to combat various infectious diseases is expected to drive this industry over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising immunization activities against preventable diseases such as diphtheria, whooping cough, tetanus and poliomyelitis in developing countries such as India and China along with other South East Asian nations.
Growth Factors:
- Increasing demand for preventive healthcare services owing to the rising awareness about various diseases and their prevention methods is expected to drive the growth of vaccine particulate adjuvants market over the forecast period.
- Growing number of research and development activities for new vaccine formulations is anticipated to propel the demand for vaccine particulate adjuvants over the next few years.
- Rising prevalence of infectious diseases across the globe is expected to create a positive impact on overall growth of this market in near future.
- Technological advancements in manufacturing process and increasing R&D investments are likely to boost adoption rates of vaccine particulate adjuvants products globally .
Scope Of The Report
Report Attributes
Report Details
Report Title
Vaccine Particulate Adjuvants Market Research Report
By Type
Oral, Subcutaneous, Intranasal, Intramuscular, Intradermal, Others
By Application
Infectious Diseases, Cancer, Others
By Companies
Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc (US), Novavax, Inc (US), SPI Pharma, Inc (US), Invivogen (US), Avanti Polar Lipids, Inc (US), MVP Laboratories, Inc (US), OZ Biosciences (France)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Vaccine Particulate Adjuvants Market Report Segments:
The global Vaccine Particulate Adjuvants market is segmented on the basis of:
Types
Oral, Subcutaneous, Intranasal, Intramuscular, Intradermal, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Diseases, Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Brenntag Biosector (Denmark)
- CSL Limited (Australia)
- SEPPIC (France)
- Agenus, Inc (US)
- Novavax, Inc (US)
- SPI Pharma, Inc (US)
- Invivogen (US)
- Avanti Polar Lipids, Inc (US)
- MVP Laboratories, Inc (US)
- OZ Biosciences (France)
Highlights of The Vaccine Particulate Adjuvants Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Subcutaneous
- Intranasal
- Intramuscular
- Intradermal
- Others
- By Application:
- Infectious Diseases
- Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vaccine Particulate Adjuvants Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vaccine particulate adjuvants are substances that are added to vaccines to help the vaccine work better. They can be made of different materials, including aluminum, iron oxide, and silicon dioxide.
Some of the key players operating in the vaccine particulate adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc (US), Novavax, Inc (US), SPI Pharma, Inc (US), Invivogen (US), Avanti Polar Lipids, Inc (US), MVP Laboratories, Inc (US), OZ Biosciences (France).
The vaccine particulate adjuvants market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Vaccine Particulate Adjuvants Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Vaccine Particulate Adjuvants Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Vaccine Particulate Adjuvants Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Vaccine Particulate Adjuvants Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Vaccine Particulate Adjuvants Market Size & Forecast, 2018-2028
4.5.1 Vaccine Particulate Adjuvants Market Size and Y-o-Y Growth
4.5.2 Vaccine Particulate Adjuvants Market Absolute $ Opportunity
Chapter 5 Global Vaccine Particulate Adjuvants Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Vaccine Particulate Adjuvants Market Size Forecast by Type
5.2.1 Oral
5.2.2 Subcutaneous
5.2.3 Intranasal
5.2.4 Intramuscular
5.2.5 Intradermal
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Vaccine Particulate Adjuvants Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Vaccine Particulate Adjuvants Market Size Forecast by Applications
6.2.1 Infectious Diseases
6.2.2 Cancer
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Vaccine Particulate Adjuvants Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Vaccine Particulate Adjuvants Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Vaccine Particulate Adjuvants Analysis and Forecast
9.1 Introduction
9.2 North America Vaccine Particulate Adjuvants Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Vaccine Particulate Adjuvants Market Size Forecast by Type
9.6.1 Oral
9.6.2 Subcutaneous
9.6.3 Intranasal
9.6.4 Intramuscular
9.6.5 Intradermal
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Vaccine Particulate Adjuvants Market Size Forecast by Applications
9.10.1 Infectious Diseases
9.10.2 Cancer
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Vaccine Particulate Adjuvants Analysis and Forecast
10.1 Introduction
10.2 Europe Vaccine Particulate Adjuvants Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Vaccine Particulate Adjuvants Market Size Forecast by Type
10.6.1 Oral
10.6.2 Subcutaneous
10.6.3 Intranasal
10.6.4 Intramuscular
10.6.5 Intradermal
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Vaccine Particulate Adjuvants Market Size Forecast by Applications
10.10.1 Infectious Diseases
10.10.2 Cancer
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Vaccine Particulate Adjuvants Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Vaccine Particulate Adjuvants Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Vaccine Particulate Adjuvants Market Size Forecast by Type
11.6.1 Oral
11.6.2 Subcutaneous
11.6.3 Intranasal
11.6.4 Intramuscular
11.6.5 Intradermal
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Vaccine Particulate Adjuvants Market Size Forecast by Applications
11.10.1 Infectious Diseases
11.10.2 Cancer
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Vaccine Particulate Adjuvants Analysis and Forecast
12.1 Introduction
12.2 Latin America Vaccine Particulate Adjuvants Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Vaccine Particulate Adjuvants Market Size Forecast by Type
12.6.1 Oral
12.6.2 Subcutaneous
12.6.3 Intranasal
12.6.4 Intramuscular
12.6.5 Intradermal
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Vaccine Particulate Adjuvants Market Size Forecast by Applications
12.10.1 Infectious Diseases
12.10.2 Cancer
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Vaccine Particulate Adjuvants Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Vaccine Particulate Adjuvants Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Vaccine Particulate Adjuvants Market Size Forecast by Type
13.6.1 Oral
13.6.2 Subcutaneous
13.6.3 Intranasal
13.6.4 Intramuscular
13.6.5 Intradermal
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Vaccine Particulate Adjuvants Market Size Forecast by Applications
13.10.1 Infectious Diseases
13.10.2 Cancer
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Vaccine Particulate Adjuvants Market: Competitive Dashboard
14.2 Global Vaccine Particulate Adjuvants Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Brenntag Biosector (Denmark)
14.3.2 CSL Limited (Australia)
14.3.3 SEPPIC (France)
14.3.4 Agenus, Inc (US)
14.3.5 Novavax, Inc (US)
14.3.6 SPI Pharma, Inc (US)
14.3.7 Invivogen (US)
14.3.8 Avanti Polar Lipids, Inc (US)
14.3.9 MVP Laboratories, Inc (US)
14.3.10 OZ Biosciences (France)
